EyePoint Pharmaceuticals Inc
EYPT10.080USD
+0.370+3.81%
Market hours （ET）Quotes delayed by 15 min
693.62MMarket Cap
LossP/E TTM
More Details of EyePoint Pharmaceuticals Inc Company
EyePoint Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the business of developing and commercializing ophthalmic products for the treatment of eye diseases. The Company's pipeline leverages its Durasert technology (Durasert) for sustained intraocular drug delivery, including delivery of EYP-1901, is an investigational sustained delivery treatment for anti-vascular endothelial growth factor (anti-VEGF) mediated retinal diseases. Its additional pipeline programs include EYP-2301, a promising TIE-2 agonist, razuprotafib, formulated in Durasert E to potentially improve outcomes in serious retinal diseases. EYP-1901 is presently in Phase 2 clinical trials as a sustained delivery treatment for wet age-related macular degeneration (wet AMD), no proliferative diabetic retinopathy (NPDR), and diabetic macular edema (DME). The Company’s other products include YUTIQ, and DEXYCU.
Company Info
Ticker SymbolEYPT
Company nameEyePoint Pharmaceuticals Inc
IPO dateJan 27, 2005
CEODr. Jay S. Duker, M.D.
Number of employees165
Security typeOrdinary Share
Fiscal year-endJan 27
Address480 Pleasant Street, Suite C400
CityWATERTOWN
Stock exchangeNASDAQ Global Market Consolidated
CountryUnited States of America
Postal code02472
Phone16179265000
Websitehttps://eyepointpharma.com/
Ticker SymbolEYPT
IPO dateJan 27, 2005
CEODr. Jay S. Duker, M.D.
Company Executives
Name
Name/Position
Position
Shareholding
Change
Dr. Jay S. Duker, M.D.
Dr. Jay S. Duker, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
685.61K
+1.33%
Ms. Nancy S. Lurker
Ms. Nancy S. Lurker
Executive Vice Chairman of the Board
Executive Vice Chairman of the Board
575.46K
+1.97%
Dr. John B. Landis, Ph.D.
Dr. John B. Landis, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
142.86K
+567.59%
Ms. Karen L. Zaderej
Ms. Karen L. Zaderej
Non-Executive Independent Director
Non-Executive Independent Director
117.28K
+1.73%
Ms. Wendy F. Dicicco, CPA
Ms. Wendy F. Dicicco, CPA
Non-Executive Independent Director
Non-Executive Independent Director
107.43K
+977.87%
Mr. Stuart Duty
Mr. Stuart Duty
Non-Executive Independent Director
Non-Executive Independent Director
45.01K
--
Mr. Ramiro Ribeiro, M.D., Ph.D.
Mr. Ramiro Ribeiro, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
41.78K
--
Dr. Reginald J Sanders, M.D.
Dr. Reginald J Sanders, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Fred Hassan
Mr. Fred Hassan
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Stern
Mr. Stern
Investor Relations
Investor Relations
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Jay S. Duker, M.D.
Dr. Jay S. Duker, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
685.61K
+1.33%
Ms. Nancy S. Lurker
Ms. Nancy S. Lurker
Executive Vice Chairman of the Board
Executive Vice Chairman of the Board
575.46K
+1.97%
Dr. John B. Landis, Ph.D.
Dr. John B. Landis, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
142.86K
+567.59%
Ms. Karen L. Zaderej
Ms. Karen L. Zaderej
Non-Executive Independent Director
Non-Executive Independent Director
117.28K
+1.73%
Ms. Wendy F. Dicicco, CPA
Ms. Wendy F. Dicicco, CPA
Non-Executive Independent Director
Non-Executive Independent Director
107.43K
+977.87%
Mr. Stuart Duty
Mr. Stuart Duty
Non-Executive Independent Director
Non-Executive Independent Director
45.01K
--
Revenue Breakdown
Currency: USDUpdated: Sun, Jul 6
Currency: USDUpdated: Sun, Jul 6
FY2024
FY2023
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
By BusinessUSD
Name
Revenue
Proportion
YUTIQ
3.10M
7.16%
By RegionUSD
Name
Revenue
Proportion
United States
42.05M
97.17%
China
1.12M
2.60%
United Kingdom
100.00K
0.23%
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
YUTIQ
3.10M
7.16%
Shareholding Stats
Updated: Fri, Jul 25
Updated: Fri, Jul 25
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Cormorant Asset Management, LP
12.10%
Suvretta Capital Management, LLC
9.89%
Adage Capital Management, L.P.
9.01%
BlackRock Institutional Trust Company, N.A.
7.19%
Franklin Advisers, Inc.
5.99%
Other
55.83%
Shareholders
Shareholders
Proportion
Cormorant Asset Management, LP
12.10%
Suvretta Capital Management, LLC
9.89%
Adage Capital Management, L.P.
9.01%
BlackRock Institutional Trust Company, N.A.
7.19%
Franklin Advisers, Inc.
5.99%
Other
55.83%
Shareholder Types
Shareholders
Proportion
Hedge Fund
39.71%
Investment Advisor
28.58%
Investment Advisor/Hedge Fund
22.88%
Venture Capital
7.91%
Research Firm
5.09%
Private Equity
4.39%
Individual Investor
3.52%
Bank and Trust
1.52%
Pension Fund
0.40%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
384
78.48M
114.05%
-10.35M
2025Q1
386
76.27M
110.90%
-11.90M
2024Q4
373
75.75M
111.39%
+202.32K
2024Q3
358
60.55M
112.89%
-8.01M
2024Q2
345
60.80M
116.35%
-2.75M
2024Q1
328
57.32M
114.97%
+528.95K
2023Q4
282
52.72M
108.16%
+11.49M
2023Q3
239
37.39M
106.16%
-1.26M
2023Q2
224
35.30M
102.90%
-4.83M
2023Q1
220
33.02M
96.37%
-5.12M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Cormorant Asset Management, LP
8.32M
12.1%
--
--
Mar 31, 2025
Suvretta Capital Management, LLC
6.80M
9.89%
+21.00K
+0.31%
Mar 31, 2025
Adage Capital Management, L.P.
6.20M
9.01%
+450.00K
+7.83%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
4.95M
7.19%
+206.82K
+4.36%
Mar 31, 2025
Franklin Advisers, Inc.
4.12M
5.99%
+9.56K
+0.23%
Mar 31, 2025
The Vanguard Group, Inc.
3.82M
5.55%
+31.14K
+0.82%
Mar 31, 2025
Federated Hermes Global Investment Management Corp.
3.71M
5.39%
+2.50K
+0.07%
Mar 31, 2025
TCG Crossover Management, LLC
3.57M
5.19%
--
--
Mar 31, 2025
RA Capital Management, LP
3.18M
4.62%
--
--
Mar 31, 2025
Citadel Advisors LLC
2.29M
3.32%
-180.78K
-7.33%
Mar 31, 2025
View more
Related ETFs
Updated: Sat, Aug 2
Updated: Sat, Aug 2
Name
Proportion
Virtus LifeSci Biotech Clinical Trials ETF
0.96%
SPDR S&P Pharmaceuticals ETF
0.79%
Simplify Health Care ETF
0.57%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
0.56%
Federated Hermes MDT Small Cap Core ETF
0.37%
iShares Micro-Cap ETF
0.13%
ProShares Ultra Nasdaq Biotechnology
0.07%
Invesco Nasdaq Biotechnology ETF
0.07%
iShares Russell 2000 Value ETF
0.04%
Avantis US Small Cap Equity ETF
0.04%
View more
Virtus LifeSci Biotech Clinical Trials ETF
Proportion0.96%
SPDR S&P Pharmaceuticals ETF
Proportion0.79%
Simplify Health Care ETF
Proportion0.57%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
Proportion0.56%
Federated Hermes MDT Small Cap Core ETF
Proportion0.37%
iShares Micro-Cap ETF
Proportion0.13%
ProShares Ultra Nasdaq Biotechnology
Proportion0.07%
Invesco Nasdaq Biotechnology ETF
Proportion0.07%
iShares Russell 2000 Value ETF
Proportion0.04%
Avantis US Small Cap Equity ETF
Proportion0.04%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Dec 08, 2020
Merger
10<1
Dec 08, 2020
Merger
10<1
Dec 08, 2020
Merger
10<1
Dec 08, 2020
Merger
10<1
Date
Type
Ratio
Dec 08, 2020
Merger
10<1
Dec 08, 2020
Merger
10<1
Dec 08, 2020
Merger
10<1
Dec 08, 2020
Merger
10<1
